首页> 外文OA文献 >Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization
【2h】

Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization

机译:多重连接依赖探针扩增和荧光原位杂交检测胃癌中CCNE1,CCND1和CDK6的基因扩增

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

New and effective treatments for advanced gastric cancer are urgently needed. Cyclins E and D1 form a complex with cyclin-dependent kinase 2, 4, or 6 to regulate G1-S transition. The G1-S regulatory genes encoding cyclin E (CCNE1), cyclin D1 (CCND1), and CDK6 (CDK6) are frequently amplified in gastric cancer and may therefore influence molecularly targeted therapies against ERBB2 or EGFR when coamplified. A total of 179 formalin-fixed and paraffin-embedded gastric cancer specimens were examined for these gene amplifications by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization. Amplification of at least 1 G1-S regulatory gene was found in 35 tumors (CCNE1 amplification, 15% of samples; CCND1, 6%; CDK6, 1%). In 13 of the 35 tumors, dual-color fluorescence in situ hybridization identified coamplification of the G1-S regulatory genes with ERBB2, EGFR, and/or KRAS in single cancer nuclei. The observation that cells with G1-S regulatory gene amplification contained clonal subpopulations with coamplification of ERBB2, EGFR, or KRAS in 5 early and 3 advanced cancers suggests that amplification of the G1-S regulatory genes represents an early event, which precedes ERBB2, EGFR, or KRAS amplification. Amplified CCNE1, CCND1, and CDK6 in advanced gastric cancer may be potentially useful as direct targets for molecular therapy or for combination therapy with ERBB2 or EGFR inhibitors. Multiplex ligation-dependent probe amplification could be a useful tool for identification of patients who would benefit from such therapies. © 2016 Elsevier Inc.
机译:迫切需要针对晚期胃癌的新的有效治疗方法。细胞周期蛋白E和D1与细胞周期蛋白依赖性激酶2、4或6形成复合物,以调节G1-S过渡。在胃癌中,编码细胞周期蛋白E(CCNE1),细胞周期蛋白D1(CCND1)和CDK6(CDK6)的G1-S调节基因经常被扩增,因此当共扩增时可能会影响针对ERBB2或EGFR的分子靶向疗法。通过多重连接依赖性探针扩增和荧光原位杂交,共检查了179个福尔马林固定和石蜡包埋的胃癌标本的这些基因扩增。在35个肿瘤中发现了至少1个G1-S调节基因的扩增(CCNE1扩增,样品的15%; CCND1,6%; CDK6,1%)。在35种肿瘤中的13种中,双色荧光原位杂交鉴定了单个癌症细胞核中G1-S调节基因与ERBB2,EGFR和/或KRAS的共扩增。在5例早期和3例晚期癌症中,具有G1-S调节基因扩增的细胞包含克隆亚群以及ERBB2,EGFR或KRAS的共同扩增,这表明G1-S调节基因的扩增代表了一个早期事件,其先于ERBB2,EGFR ,或KRAS放大。晚期胃癌中扩增的CCNE1,CCND1和CDK6可能用作分子治疗或与ERBB2或EGFR抑制剂联合治疗的直接靶标。多重连接依赖性探针扩增可能是鉴定受益于此类疗法的患者的有用工具。分级为4 +©2016 Elsevier Inc.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号